Knowledge Check
Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.
Log in to access
Autosomal dominant polycystic kidney disease is characterised by renal cysts, hepatic cysts, intracranial aneurysms and aortic root dilatation.
It is the most common inherited disorder of the kidneys. It peaks between the ages of 30 and 40, and affects men and women equally.
Classification of Autosomal Dominant Polycystic Kidney Disease
Classification Description Type 1 ADPKD A mutation in PKD1 on chromosome 16. This is the more severe type. Type 2 ADPKD A mutation in PKD2 on chromosome 4. This is the less severe form
Cause
Mutation in PKD1 and PKD2
Pathophysiology
PKD1 and PKD2 encode polycystin-1 and polycystin-2 which are part of primary cilia
Primary cilia act as mechanosensors in renal tubular epithelial cells
Mutations in PKD1 and PKD2
Increased intracellular Ca2+ → activation of signalling pathways → cell proliferation and fluid secretion
Disrupted planar cell polarity → misoriented cell division → tubular dilation → cyst formation
The cysts expand, compress the parenchyma, and lead to ischaemia → fibrosis
Similar ciliary dysfunction in other organs leads to extrarenal manifestations
Signs and symptoms
Haematuria
Loin pain
Hypertension
Recurrent UTI
Urolithiasis
Headache
This may be due to a ruptured berry aneurysm
Renal failure
This occurs in the 5th decade of life
Physical examination
Palpable kidneys or abdominal mass
Hepatomegaly due to hepatic cysts
Abdominal wall hernias
Cardiac murmur
Differentials
Autosomal recessive polycystic kidney disease (ARPKD)
In ARPKD, symptoms present soon after birth
Medullary cystic renal disease
In medullary cystic renal disease, the kidneys are smaller and recurrent gout is common
Acquired cystic kidney disease
Simple renal cysts
Tuberous sclerosis
Von-Hippel-Lindau syndrome
Investigations
Renal ultrasound is the first-line imaging modality
The diagnosis can be made based on the Ravine criteria which counts the number of renal cysts according to the age group
MRI is more sensitive than ultrasound for smaller cysts
MRI can also be used to screen for intracranial aneurysms
Urea and creatinine to assess renal function
Urinalysis for haematuria or proteinuria
Genetic testing when imaging is inconclusive
Treatment
Referral to a nephrologist
Treat hypertension
Treat renal pain
Treat UTIs
Treat urolithiasis
Renal replacement therapy if indicated
V2 receptor antagonist (Tolvaptan)
This may slow the progression of cysts and renal insufficiency
Complications
Biochemistry
ACTH P: <80 ng/L
ALT P: 5–35 U/L
Albumin P: 35–50 g/L
Aldosterone P: 100–500 pmol/L
Alk. phosphatase P: 30–130 U/L
α-Amylase P: 0–180 IU/dL
α-Fetoprotein S: <10 kU/L
Angiotensin II P: 5–35 pmol/L
ADH P: 0.9–4.6 pmol/L
AST P: 5–35 U/L
Bicarbonate P: 24–30 mmol/L
Bilirubin P: 3–17 μmol/L
BNP P: <50 ng/L
CRP P: <10 mg/L
Calcitonin P: <0.1 mcg/L
Calcium (ionized) P: 1.0–1.25 mmol/L
Calcium (total) P: 2.12–2.60 mmol/L
Chloride P: 95–105 mmol/L
Cholesterol P: <5.0 mmol/L
VLDL P: 0.128–0.645 mmol/L
LDL P: <2.0 mmol/L
HDL P: 0.9–1.93 mmol/L
Cortisol AM P: 450–700 nmol/L
Cortisol Midnight P: 80–280 nmol/L
CK ♂ P: 25–195 U/L
CK ♀ P: 25–170 U/L
Creatinine P: 70–100 μmol/L
Ferritin P: 12–200 mcg/L
Folate S: 2.1 mcg/L
FSH P: 2–8 U/L ♂; >25 menopause
GGT ♂ P: 11–51 U/L
GGT ♀ P: 7–33 U/L
Glucose (fasting) P: 3.5–5.5 mmol/L
Growth hormone P: <20 mu/L
HbA1C (DCCT) B: 4–6%
HbA1C (IFCC) B: 20–42 mmol/mol
Iron ♂ S: 14–31 μmol/L
Iron ♀ S: 11–30 μmol/L
Lactate (venous) P: 0.6–2.4 mmol/L
Lactate (arterial) P: 0.6–1.8 mmol/L
LDH P: 70–250 U/L
LH P: 3–16 U/L
Magnesium P: 0.75–1.05 mmol/L
Osmolality P: 278–305 mosmol/kg
PTH P: 0.8–8.5 pmol/L
Potassium P: 3.5–5.3 mmol/L
Prolactin ♂ P: <450 U/L
Prolactin ♀ P: <600 U/L
PSA P: 0–4 mcg/mL
Protein (total) P: 60–80 g/L
Red cell folate B: 0.36–1.44 μmol/L
Renin (erect) P: 2.8–4.5 pmol/mL/h
Renin (recumbent) P: 1.1–2.7 pmol/mL/h
Sodium P: 135–145 mmol/L
TBG P: 7–17 mg/L
TSH P: 0.5–4.2 mU/L
T4 P: 70–140 nmol/L
Free T4 P: 9–22 pmol/L
TIBC S: 54–75 μmol/L
Triglycerides P: 0.50–2.3 mmol/L
T3 P: 1.2–3.0 nmol/L
Troponin T P: <0.1 mcg/L
Urate ♂ P: 210–480 μmol/L
Urate ♀ P: 150–390 μmol/L
Urea P: 2.5–6.7 mmol/L
Vitamin B12 S: 0.13–0.68 nmol/L
Vitamin D S: 50 nmol/L
Arterial Blood Gases
pH 7.35–7.45
PaCO₂ 4.7–6.0 kPa
PaO₂ >10.6 kPa
Base excess ±2 mmol/L
Urine
Cortisol (free) <280 nmol/24h
Hydroxyindole acetic acid 16–73 μmol/24h
Hydroxymethylmandelic acid 16–48 μmol/24h
Metanephrines 0.03–0.69 μmol/mmol cr.
Osmolality 350–1000 mosmol/kg
17-Oxogenic steroids ♂ 28–30 μmol/24h
17-Oxogenic steroids ♀ 21–66 μmol/24h
17-Oxosteroids ♂ 17–76 μmol/24h
17-Oxosteroids ♀ 14–59 μmol/24h
Phosphate (inorganic) 15–50 mmol/24h
Potassium 14–120 mmol/24h
Protein <150 mg/24h
Protein/creatinine ratio <3 mg/mmol
Sodium 100–250 mmol/24h
Haematology
WCC 4.0–11.0 ×10⁹/L
RBC ♂ 4.5–6.5 ×10¹²/L
RBC ♀ 3.9–5.6 ×10¹²/L
Hb ♂ 130–180 g/L
Hb ♀ 115–160 g/L
PCV ♂ 0.4–0.54 L/L
PCV ♀ 0.37–0.47 L/L
MCV 76–96 fL
MCH 27–32 pg
MCHC 300–360 g/L
RDW 11.6–14.6%
Neutrophils 2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes 1.0–4.5 ×10⁹/L (20–45%)
Eosinophils 0.04–0.44 ×10⁹/L (1–6%)
Basophils 0–0.10 ×10⁹/L (0–1%)
Monocytes 0.2–0.8 ×10⁹/L (2–10%)
Platelets 150–400 ×10⁹/L
Reticulocytes 0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time 10–14 s
APTT 35–45 s
Paediatric
Pulse Rate (bpm)
Neonate 140–160
Infant <1yr 120–140
1–5 years 110–130
5–12 years 80–120
>12 years 70–100
Respiratory Rate (tachypnoea)
0–2 months ≥60/min
2–12 months ≥50/min
1–5 years ≥40/min
>5 years ≥30/min
Blood Pressure (mmHg)
Term 65/45
1 year 75/50
4 years 85/60
8 years 95/65
10 years 100/70
Weight Formulas
3–12 months (a + 9)/2 kg
1–6 years 2a + 8 kg
>6 years (7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn 13–20
1 month 11–18
2 months 10–15
1–2 years 10–13
>2 years 11–14
MUAC (6 months–5 years)
Obese >17.5 cm
Normal 13.5–17.4 cm
At risk 12.5–13.4 cm
Moderate malnutrition 11.5–12.4 cm
Severe malnutrition <11.5 cm
Developmental Milestones
Social smile 1.5 months
Head control 4 months
Sits unsupported 7 months
Crawls 10 months
Stands unsupported 10–12 months
Walks 12–13 months
Talks 18 months
CSF WBC (/mm³)
Term newborn 0–25
>2 weeks 0–5